SpecificationsOrganism/cell line/tissue*Homo sapiens*/A375 melanoma cell lineSexNASequencer or array typeAffymetrix Primeview® Human Gene Expression ArraysData formatRaw and Normalized DataExperimental factorsMonocytes *vs.* untreated tumor-monocyte co-cultures (A375-MDSC) *vs.* MIF inhibitor-treated tumor-monocyte co-cultures (A375-MDSC + 4-IPP)Experimental featuresExpression profiling of healthy donor CD14^+^ monocytes cultured for 64 h in the absence of (cultured monocytes), or in the presence of A375 melanoma cells (A375-MDSC) or treated with MIF inhibitor, 4-IPP (MDSC + 4-IPP; 100 μM, day 0 and 50 μM, day 2).ConsentAll samples were obtained after informed consentSample source locationLouisville, KY

1. Direct link to deposited data {#s0005}
================================

Deposited data can be found here: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73333>.

2. Experimental design, materials, and methods {#s0010}
==============================================

2.1. Monocyte isolation and cell lines {#s0015}
--------------------------------------

Peripheral blood was collected from healthy donors. Peripheral blood mononuclear cells (PBMCs) were isolated from the peripheral blood by density gradient centrifugation (Ficoll-Hypaque, GE, Piscataway, NJ). Monocytic CD14^+^ cells were isolated from PBMCs using anti-CD14 magnetic microbeads and the autoMACS Pro Separator (Miltenyi Biotec, Auburn, CA), per manufacturer\'s instructions. Purity of isolated cell populations was \> 90%, as evaluated by flow cytometry. Melanoma cell line \[A375\] (ATCC® CRL-1619™) was purchased from ATCC (Manassas, VA) and maintained in DMEM containing 10% (v/v) FBS. We do not culture this cell line for longer than 6--8 weeks and all cell-stocks came from thawed vials that were frozen at passage two after receiving from ATCC. A375 cell line was authenticated by ATCC cell bank using the Short Tandem Repeat (STR) profiling.

2.2. *In vitro* generation of human MDSC and MIF-inhibitor treatment {#s0020}
--------------------------------------------------------------------

We established an *in vitro* model of melanoma cell-line-induced MDSCs that faithfully recapitulates patient-derived CD14^+^ HLADR^−/low^ monocytic MDSC phenotype and function [@bb0045], [@bb0050]. CD14^+^ cells (1 × 10^6^ cells/well), isolated from PBMCs obtained from healthy donors, were co-cultured with A375 tumor cells (5 × 10^5^ cells/well) in complete IMDM (supplemented with 10% human AB serum \[Sigma-Aldrich, St. Louis, MO\], L-glutamine \[2 mM\], and penicillin/streptomycin) per well in a 6-well plate (BD Falcon). Tumor/monocyte co-cultures were treated twice with the small molecule inhibitor of MIF, 4-IPP (100 μM on day 0 and 50 μM on day 2), or 0.1% DMSO (vehicle control). A375 co-cultured monocytes (both vehicle-treated and 4-IPP-treated) and control monocytes cultured without tumor cells (cultured monocytes) were gently harvested after 64--68 h of culture and CD11b^+^ cells (A375-MDSCs) were purified with anti-CD11b^+^ microbeads and autoMACS separator (Miltenyi Biotec) ([Fig. 1](#f0005){ref-type="fig"}). Purity of isolated cell populations was \> 90% as evaluated by flow cytometry. We refer to the CD11b^+^ cells isolated from the A375 monocyte co-cultures as A375-MDSCs although we are cognizant of the fact that these cells represent a heterogenous population of cells [@bb0010]. The percentage of CD14^+^ CD11b^+^ CD33^+^ HLADR^−/low^ cells are substantially increased in A375-monocyte co-cultures in comparison to that of monocytes cultured in the absence of melanoma cells---an expression signature that closely corresponds to monocytic MDSCs isolated from late stage melanoma patients [@bb0050], [@bb0055], [@bb0065]. Furthermore, in contrast to tumor cell-free cultured monocytes, A375-MDSCs exhibit potent suppressive activity against autologous T cell proliferation and IFN-γ production [@bb0045], [@bb0050].

2.3. Microarray Analysis {#s0025}
------------------------

Gene expression profiles of vehicle-treated A375-MDSCs or 4-IPP-treated A375-MDSCs (A375-MDSC + 4-IPP) were compared to that obtained using monocytes cultured without tumor cells ([Fig. 1](#f0005){ref-type="fig"}). Total RNA from cultured monocytes, vehicle-treated, and 4-IPP-treated A375-MDSCs (n = 3) were isolated post-68 h *in vitro* culture and analyzed over a microarray. For RNA extraction, cells were lysed in buffer RLT (Qiagen, Valencia, CA), homogenized, and purified using RNeasy mini kit (Qiagen) following manufacturer\'s instructions. Integrity of RNA was checked using a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). Biotinylated cRNA was prepared from 100 ng of total RNA according to the standard protocol for Affymetrix 3′ IVT Express Plus Reagent kit. Following fragmentation, cRNA was hybridized for 16 h at 45 °C to Affymetrix Primeview Human arrays according to the GeneChip 3′ Array Hybridization User Manual from Affymetrix. The arrays were processed following the manufacturer recommended wash and stain protocol on an Affymetrix FS-450 fluidics station and scanned on an Affymetrix GeneChip scanner. The resulting .cel files were imported into Partek Genomics Suite 6.6 and transcripts were normalized and summarized using RMA as normalization and background correction method. Contrasts in a 1-way ANOVA were set up to compare the treatments of interest. Step-up False Discovery Rate was chosen as multiple test correction for the resulting *p*-values. The microarray datasets discussed in current study have been deposited in NCBI\'s Gene Expression Omnibus (GEO; [www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo){#ir0015}) and are accessible through GEO Series accession number [GSE73333](ncbi-geo:GSE73333){#ir0020}.

3. Conclusions {#s0030}
==============

A microarray analysis of normal monocytes, vehicle-treated-A375-MDSCs, and 4-IPP-treated A375-MDSCs was performed to identify downstream MIF effectors that could be responsible for MIF-dependent phenotypic and functional contributions to human MDSCs. Melanoma cell line-induced MDSC transcriptome reveals a unique gene expression profile that is largely reversed to normal monocyte levels by MIF inhibition. Inflammatory cytokines, chemokines/chemokine receptors, matrix metalloproteases, angiogenic growth factors, and arachidonic acid/prostaglandin-generating enzymes are all differentially expressed in A375-MDSCs and restored to "normal" levels by MIF inhibition. These results are discussed in detail in the article published by Yaddanapudi et al. (2015) in Cancer Immunology Research [@bb0050].
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![Schematic representation of the experimental design for the microarray analysis. (A) Normal donor CD14^+^ monocytes were co-cultured with human A375 melanoma cells for 68 h (MDSC induction). CD11b^+^ A375-MDSCs were isolated from the co-cultures by anti-CD11b^+^ microbead labeling and magnetic column separation (MDSC isolation). RNA for the microarray analysis was subsequently isolated from the purified A375-MDSCs; (B) 4-IPP (50 μM) was added during the A375:monocyte MDSC induction phase (A375-MDSC + 4-IPP), which was followed by the isolation of RNA from the purified 4-IPP-treated MDSCs; and (C) RNA was isolated from monocytes that were cultured for 68 h without tumor cells (cultured monocytes control).](gr1){#f0005}
